

A joint meeting provided by
UK NEQAS for ICC & ISH, UK NEQAS for Molecular Genetics & UK NEQAS for CPT
The Beaumont Estate Hotel & Conference Centre
Old Windsor, UK

Molecular Pathology: Focusing on Patients October 12th – 14th 2012

2ND Announcement

Friday 12th October

12.00 Registration and buffet lunch

Lung Cancer: pathology, personalised therapy & related biomarkers

14.00 **Introduction by chairman**

Professor Adrienne Flanagan (UCL Cancer Institute)

14.45 **Histopathology of lung cancer**

Dr Mary Falzon (University College London Hospitals)

15.30 *Refreshments and trade*

15.50 **“Personalized Therapy for Advanced Non-small Cell Lung Cancer**

Professor Roy Herbst (Yale Comprehensive Cancer Centre)

16.30 **ALK Rearrangements in Non-Small Cell Lung Cancer**

Dr Jens Dhein (Abbott Molecular)

17.20 Summary and discussion

Saturday 13th October

Novel slide based testing

9.00 **Introduction by chairman**

Professor Bharat Jasani (University of Wales College of Medicine)

9.05 **Modern slide based predictive testing**

Dr Kenneth Bloom (GE Health Care- Clariant)

9.50 **Current status of IHC4 in breast cancer**

Professor Mitch Dowsett (ICR Royal Marsden Hospital)

10.35 *Refreshments and trade*

Breast Cancer

11.00 **Usual and unusual molecular Her-2/neu signal patterns in breast carcinoma.**

Dr Matteo Brunelli (Verona, Italy)

11.50 **HER2 IQFISH pharmDx™. Get your In Situ Hybridization Results in 3½ hours.**

Performance Evaluation – Results from Intra-Laboratory Comparison Study

Dr Iris Nagelmeier (Targos)

Clinical Perspectives – How will this new Technology Change the Use of ISH in Cancer Diagnostics and the value for Oncologist and Patients

Dr Kenneth Bloom (GE Health Care- Clariant)

12.35 *Lunch and trade*

14.00 **Introduction by chairman**

Andrew Dodson (Liverpool Royal Infirmary)

14.05 **The Roche oncology pipeline**

Dr Julian Cole (Roche Products Ltd)

14.50 **The Roche biomarking pipeline**

Dr Eric Walk, (Ventana – Tucson)

15.35 Refreshments and trade

GI Tract: pathology, personalised medicine & targeted therapy

16.00 **Pathology of the GI tract**

Professor Marco Novelli (UCLH)

16.45 **The impact of cetuximab therapy on colorectal cancer**

TBC

17.30 Summary and discussion

Sunday 14th October

Selected Topics

9.00 **Introduction by chairman**

Dr Matteo Brunelli (Verona, Italy)

9.05 **Aspects of Quality Assessment (Part I)**

Dr Merdol Ibrahim (UK NEQAS –ICC & ISH, UCL)

9.40 **Aspects of Quality Assessment (Part II)**

Suzanne Parry (UK NEQAS –ICC & ISH, UCL)

10.15 *Refreshments and trade*

10.45 **Oncotype DX**

Dr Christer Svedman (Genomic Health)

11.30 **The role of NICE in biomarking**

Professor Ian Cree (Warwick University Hospital)

12.15 Summary, discussion and presentation of poster prizes.

12.30 *Lunch and depart*

Satellite meetings

Saturday 13th October

9.00- 17.00. UK NEQAS –Molecular Genetics (Meeting Leader – Dr Sandi Deans, UKNEQAS -MG)

10.00 – 16.00. UKNEQAS –ICC & ISH (Meeting Leader – Dr Merdol Ibrahim, UKNEQAS –ICC & ISH)

Delegates are invited to join an assessment panel to assess immunostained slides using the UK NEQAS assessment criteria. Participants of the scheme can bring some of their own slides for assessment too. The assessment will be open to all routinely employed antibodies and not just those requested by UK NEQAS.

12.30 – 14.00. Workshop for ALK in Non-Small Cell Lung Cancer (Workshop Leader - Michael Gandy, UCL-Advanced Diagnostics)

Sunday 14th October

9.00 – 12.30. UK NEQAS –CPT (Meeting Leader – Garry Thompson (UKNEQAS-CPT)

9.30 – 11.00. Workshop on Gastric HER-2 (Workshop Leader – Dr Iris Nagelmeier, Targos)

POSTERS

Abstracts are invited for posters – closing date 31st August 2012

Royal College and IBMS CPD points – to be confirmed

